Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GlaxoSmithKline

Shares of Vir Biotechnology Inc. gained 1.9% in premarket trading on Wednesday after the company and GlaxoSmithKline said the European Commission purchased 220,00 doses of their investigational COVID-19 antibody treatment. The therapy is a single-dose monoclonal antibody that is being tested as a treatment to ward off severe disease in some high-risk COVID-19 patients.

Europe buys 220,000 doses of Vir, GSK's experimental COVID-19 treatment

LONDON and SAN FRANCISCO, July 28, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, an investigational single dose SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. The Joint Procurement Agreement enables participating European Union (EU) Member States to quickly purchase sotrovimab, following local emergency authorization or authorization at the EU level, to treat high-risk patients with COVID-19 who may benefit from early treatment with sotrovimab.

GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab

SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021.

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021

Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.

Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study

Vir Biotechnology Inc (NASDAQ: VIR) has dosed the first patient in the Phase 2 MARCH trial evaluating VIR-2218 in combination with VIR-3434 to treat patients with chronic hepatitis B virus (HBV) infection. The combination treatment is designed to achieve a functional cure (defined as undetectable HBsAg and sustained suppression of HBV DNA).

Vir Biotechnology Starts Dosing In Mid-Stage Hepatitis B Trial With Combination Therapy

Shares of Vir Biotechnology Inc. gained 0.6% in trading on Thursday after the company said it started an open-label Phase 2 clinical trial for its experimental hepatitis B treatment. The study combines two investigational therapies with the aim of developing what Vir calls a "functional cure.

Vir initiates open-label Phase 2 study for experimental hepatitis B treatment

AbbVie

AstraZeneca

Eli Lilly

Regeneron Pharmaceuticals

Here's how several leading COVID-19 antibody therapies compare based on pre-clinical testing.

These COVID Therapies Appear to Be the Best and Worst at Treating New Variants

The sample size was small, but the results were impressive.

GlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know

Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection.  The results were presented at the European Association for the Study of the Liver International Liver Congress 2021.

Vir Biotech's HBV Candidates Show Positive Safety Profiles

Shares of Vir Biotechnology Inc. gained 3.1% in premarket trading on Friday after the company shared positive data from mid-stage and early-stage clinical trials for its experimental hepatitis C treatments. One candidate, VIR-2218, was tested subcutaneously in 32 patients with chronic hepatitis B infections.

Vir's 'sock gains on early results from clinical trials for its hepatitis B treatment candidate

– Results demonstrate positive safety profiles and a reduction in HBsAg for two novel  HBV therapies administrated as monotherapy or in combination with other agents –

Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021

Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make better HIV medicines.

Glaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating sotrovimab in high-risk adult outpatients with mild-to-moderate COVID-19. Data demonstrated a 79% reduction in hospitalization for more than 24 hours or death compared with placebo after 29 days.

GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients

Shares of Vir Biotechnology Inc. gained 1.4% in premarket trading on Monday after the company said the COVID-19 antibody treatment it developed with GlaxoSmithKline cut the risk of hospitalization and death among adults at high risk. The confirmatory data came from a Phase 3 clinical trial that was used to inform the emergency-use authorization granted to sotrovimab in late May.

Vir, GSK say new data confirms their COVID-19 treatment can reduce hospitalization and death

– Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces  hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk  of progression to severe disease –

GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab

Gritstone Oncology Inc

RedHill Biopharma

Coronavirus players may deliver strong returns well into the future.

3 Top Biotech Picks for June

– Company to host conference call and webcast on Friday, June 25, 2021 at 11:00 AM ET – – Company to host conference call and webcast on Friday, June 25, 2021 at 11:00 AM ET –

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021

SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9th at 12:00 pm PT / 3:00 pm ET.

Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference

Vir's antibody treatment is addressing one of the biggest COVID challenges.

15 Words From Vir Biotechnology's CEO May Mean Market Dominance

There are now three antibody-based treatments available in the U.S. to treat adults and teens with mild or moderate forms of COVID-19, though all require intravenous infusions and are not the kind of medications that can be picked up at a local pharmacy.

The FDA authorized the third monoclonal antibody treatment. Here's why Vir and GSK say the U.S. still needs COVID-19 therapies

GlaxoSmithKline and Vir Biotechnology won FDA authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. The post The Surprising Move Vir Stock Made After Winning Covid Drug Authorization appeared first on Investor's Business Daily.

The Surprising Move Vir Stock Made After Winning Covid Drug Authorization

Vir Biotechnology Inc (NASDAQ: VIR) shares jumped roughly 10% in after-hours trading on Wednesday as the company received emergency use authorisation for its COVID-19 drug from the U.S Food and Drug Administration (FDA). The federal agency's approval for Sotrovimab (VIR-7831) that the biotech firm developed in collaboration with GlaxoSmithKline applies to pediatric patients and high-risk […] The post Vir Biotechnology gains 10% after receiving EUA for its COVID-19 treatment appeared first on Invezz.

Vir Biotechnology gains 10% after receiving EUA for its COVID-19 treatment

Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.

Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod

The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and GlaxoSmithKline Plc (NYSE: GSK) for treating mild-to-moderate COVID-19 in people aged 12 years and older. The EUA comes after Vir's antibody proved 85% effective at preventing hospitalization in high-risk, newly diagnosed COVID-19 patients.

Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug

GlaxoSmithKline plc and Vir Biotechnology Inc. said the U.S. Food and Drug Administration has granted emergency use authorization to its single-dose monoclonal antibody treatment sotrovimab in mild-to-moderate COVID-19 in adults and pediatric patients who are at high risk of severe illness, including hospitalization or death. Vir Chief Executive George Scangos said an interim analysis of data produced in a laboratory found the antibody treatment showed an 85% reduction in all-cause hospitalizations or death and is effective against all known variants of concern, including the emerging variant from India.

News for Vir Biotechnology Stock (VIR)